PUBLIC COMPANY
saveBAUSCH
USupdated 3mo ago
community read0 votes
pipeline
2
marketed
0
phase 3
0
catalysts ytd
0
approvals ytd
0
recalls ytd
0
Pipeline(2)
pipeline depth2 products
2Unknown
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →🐶 Hiring Signal
News
- FDA warning letter accuses Bausch & Lomb of lacking commitment to remediationAfter reviewing Bausch & Lomb’s response to its observations, the FDA questioned whether the company is committed to implementing significant design remediations.biospace · 1d ago
- FDA warns Bausch and Lomb, Indian API maker for GMP issuesThe US Food and Drug Administration (FDA) recently issued warning letters to ophthalmic product maker Bausch and Lomb and an Indian active pharmaceutical ingredient (API) maker for violations of go…raps · 2d ago
- Zepbound may cut healthcare costs, study says; Summit, Akeso drug hits in another China trialA real-world study suggests Zepbound use could reduce the rates of hospital stays and ER visits. Elsewhere, McKesson sprung for a multibillion-dollar deal and J&J nabbed a noteworthy approval.biopharma_dive · 22d ago
- Bausch + Lomb advances dry eye disease drug to Phase 3 despite mid-stage failWhile Bausch + Lomb’s dual-action eye drops failed to outperform active comparators at day 29, the investigational asset showed significant superiority at day 15.biospace · 23d ago
- Bausch + Lomb plans Phase 3 trial for dry eye drop, despite missing mid-stage goalBausch + Lomb’s dual-action drop for dry eye failed a Phase 2 study, the company exclusively told Endpoints News on Monday. But CEO Brent Saunders claims it was a "better outcome than we had ever h…endpoints · 24d ago
- Narcan maker Emergent BioSolutions eliminates top R&D role in sweeping restructuringTwo and a half years into his tenure as Emergent BioSolutions CEO, Joseph Papa is executing another round of restructuring to align the business with “current business realities.”fiercebiotech · 1mo ago
- STAT+: Sandoz to pay $478.5 million to settle price-fixing allegations in long-running battle with statesSandoz agreed to pay $478.5 million to settle allegations that the company engaged in a conspiracy to artificially inflate and manipulate prices.stat · 1mo ago
- STAT+: Glenmark to pay $29.6 million to settle price-fixing allegations in long-running battle with statesGlenmark Pharmaceuticals agreed to pay $29.6 million to settle price-fixing allegations in a long-running battle with dozens of states.stat · 2mo ago
- Hansoh meets Phase 3 SCLC goal; FDA approves Sanofi on-body injectorPlus, news about Huntington's, Fate Therapeutics and Bausch + Lomb. 🇨🇳 Hansoh touts Phase 3 success for GSK-partnered ADC: The program, called risvutatug rezetecan or Ris-Rez, met its primary end…endpoints · 2mo ago
- AstraZeneca’s ‘extensive’ obesity drug push; $125M for ultrasound-aided genetic medicineNewly published data convinced AstraZeneca to conduct a sprawling late-stage program for its GLP-1 pill. Elsewhere, Bausch + Lomb will lay off 119 employees and Cartesian boosted its ‘in vivo’ cell…biopharma_dive · 3mo ago
comments(0)
5-min edit window · permanent after that